Background: A phase I study was designed for the amalgamation of two previously studied antisarcoma regimens (ifosfamide + doxorubicin and mitomycin + doxorubicin + cisplatin) supported by molgramostim. Thus, we hoped to develop a better regimen for the treatment of advanced sarcomas.
Introduction
Although an increased proportion of patients with advanced sarcomas may experience temporary tumor regression as higher doses of active antisarcoma agents are used, the long-term benefits of these more dose intense chemotherapy efforts have been generally unimpressive [1] . Most recently a European Organization for Research and Treatment of Cancer (EORTC) phase III study designed to confirm the earlier apparent doubling of objective regression rates in patients receiving 50% increased doxorubicin doses failed to show any therapeutic enhancement over the EORTC standard dose ifosfamide-doxorubicin regimen [2] . Their earlier phase II demonstration of a 45% objective tumor regression rate had utilized the same three-week schedule and doses of ifosfamide (5 gm/m 2 ) and doxorubicin (75 mg/ m 2 ) as did the high-dose limb of this recent phase III trial, which produced a regression rate of only 21% [3] . In their verbal May, 1996 presentation to the American Society of Clinical Oncology, these authors reported that the Escherichia coli derived, nonglycosylated rhGM-CSF (molgramostim), which had been given subcutaneously for 14 days following each cycle of chemotherapy in their original phase II study, was not available for their phase III confirmatory effort. Thus, yeast derived, glycosylated rhGM-CSF (sargramostim) was substituted for molgramstim in the same moderate 250 ug/m 2 daily subcutaneous doses as used earlier in the phase II trial. Could this difference in cytokine products have influenced these surprisingly different therapeutic outcomes?
Between 1991 and 1993 we performed a phase I study to establish a GM-CSF supported regimen for sarcoma treatment based on two relatively active combinations previously used by the Eastern Cooperative Oncology Group (ECOG) in a comparative study of advanced soft tissue sarcomas [4] . This effort to integrate ifosfamide-doxorubicin with mitomycin-doxorubicin-cisplatin yielded ifosfamide-doxorubicin-cisplatin (IAP) + molgramostim and finally ifosfamide-mitomycin-doxorubucin-cisplatin (IMAP) + molgramostim. During that study we observed unexpectedly favorable antisarcoma responses, as reported preliminarily three years ago [5] . The present report confirms that these sarcoma patients have also experienced uncommonly favorable survival. These preliminary observations and the EORTC results will be discussed as supporting the idea that molgramostim might contribute to the antisarcoma effects of cancer chemotherapy. We believe that molgramostim should be once again made available for clinical research so that phase III studies to test this hypothesis can be done. 
Patients and methods
Patients at least age 18 years with histologically proven advanced cancer for which no better treatment was known were accepted if they had objectively evaluable disease, normal bone marrow function and hepatic function, and serum creatinine no greater than 0.3 ug/dl above the upper normal limit. Pregnant or nursing women and patients who had received any previous antineoplastic drug treatment or radiation therapy were excluded, as were patients with active heart disease or infection. All patients had ECOG performance status of 0,1 or 2.
The initial regimen (level I) involved ifosfamide 2500 mg/m 2 , MESNA 500 mg/m 2 x 5, doxorubicin 40 mg/m 2 , and cisplatin 60 mg/m 2 all given i.v. on day 0 of each four-week cycle followed by molgramostim (non-glycosylated, E. coli derived rhGM-CSF, Schering-Plough/Sandoz, Kenilworth, NJ) given subcutaneously 5 ug/kg every 12 hours on days 1-14 of each cycle (Table 1) . At intensity level II the same cytotoxic drug regimen from level I was moved to day 1 preceded by ifosfamide 2500 mg/m 2 and MESNA 500 mg/m 2 x 5 on day 0. At level III mitomycin 4 mg/m 2 was added to the day 1 regimen. For levels II and III, molgramostim 5 ug/kg was given every 12 hours for 14 days beginning the day after completion of chemotherapy, and in addition this same dose schedule was given for four days beginning six days prior to each treatment cycle. These molgramostim treatment schedules had been developed earlier for maximal bone marrow stimulation purposes [6] . Used in this way molgramostim had proven to be toxic but usually tolerable.
Patients were assigned sequentially to intensity levels I through III with at least three patients studied at each level prior to opening the next one. Levels IV through VI had been planned, but these were not used because dose limiting toxicity was achieved at level III. This permitted the accrual of five patients at intensity level I, four at level II, and 12 patients at level III within our preset study limit of 21 total participants. Due to our deliberate priority favoring the recruitment of patients with advanced sarcomas 15 of the 21 participants had adult type sarcomas, and this permitted us to preliminarily observe the therapeutic effects of IAP with and without mitomycin supported by molgramostim in this category of neoplasia [5] . The other six participants in this study had mesothelioma (2), carcinosarcoma (2), adenocarcinoma of bladder, and adenocarcinoma of lung. The individual patients respectively with peritoneal carcinosarcoma and pleural mesothelioma received level I treatment, the other four non-sarcoma patients receiving level III treatment. Patients were assessed for objective tumor responses according to standard criteria.
Results
The non-sarcoma patients responded as follows: uterine carcinosarcoma -CR (five cycles, IMAP), abdominal mesothelioma -Regr. (four cycles, IMAP), peritoneal carcinosarcoma -Regr. (seven cycles, IAP), adenocarcinoma of lung -Stab, (two cycles, IMAP), pleural mesothelioma -Stab, (four cycles, IAP), and adenocarcinoma of bladder -Stab, (two cycles, IMAP).
As previously described in our preliminary report five of the 15 advanced sarcoma patients directly experienced complete tumor regression (synovial sarcoma, malignant fibrous histiocytoma, epithelioid sarcoma, osteosarcoma, and angiosarcoma), and a sixth patient with complete regression of her lung metastases has maintained overall tumor free status after the interval excision of her residual primary body wall soft tissue myxoid chondrosarcoma [5] . A seventh patient with regression of his recurrent dedifferentiated retroperitoneal liposarcoma was subsequently rendered apparently disease free by irradiation and surgery. Toxic effects of IMAP + molgramostim and further clinical details have been described in our preliminary report [5] .
Five of these 15 advanced sarcoma patients are alive more than three years after treatment began with four of them beyond four years. The actual median survival for the 15 patient group was 27 months (Figure 1) , double the usual one-year survival expectation for such patients. Although two of these five survivors have required thoracotomy (respectively four and two years ago) for the excision of pulmonary lesions and a third has required excision of an omental metastasis, we suspect that some of these patients may be true long-term survivors.
Discussion
Because any small group of advanced sarcoma patients potentially might yield exceptional therapeutic results (good or bad), we cannot be certain that this novel antisarcoma regimen has itself determined these unusually favorable therapeutic results. The qualitative excellence observed, however, might be difficult to explain simply by a favorable inadvertent selection bias. The attribution of these surprisingly favorable preliminary results to the chemotherapy or to some unrecognized favorable factor in medical management also would be difficult. We have provided patients in this study population the same standard of clinical care traditionally available for all sarcoma patients at our institution; yet the results are certainly not standard quality. We suspect that we may be seeing in these results a quality of response different than those observed previously in our treatment of advanced sarcomas using just chemotherapy. Never before have we observed such a high proportion of complete regressions and long survival in this type of disease. In a subsequent 23 patient phase II trial involving IMAP + molgramostim (according to intensity level III of the present study) and covering a broad spectrum of advanced sarcomas, we have observed responses ranging from total resistance in ordinary chondrosarcoma and adamantinoma arising in bone to dramatic and rapid complete regression in desmoplastic intra-abdominal small round cell tumors and in metastatic Ewing's sarcoma (Edmonson et al., unpublished). As might have been anticipated, word of our uncommonly successful preliminary trial served to attract to this phase II study a number of patients with truly formidable unresectable abdominal sarcomas which did not shrink. While these maturing phase II observations (six PR, three CR) do not yet permit the documentation of long-term survivors, we believe that the quality of some of these more recent regressions is provocative enough to support our call for further investigation of this regimen in phase III studies, as soon as an adequate supply of molgramostim can be provided.
Earlier, while awaiting activation of that molgramostim supported phase II study, we treated 13 similarly selected advanced adult sarcoma patients with IMAP + sargramostim, 250 ug/m 2 given by the same every 12 hour GM-CSF schedule (total 500 ug/m 2 daily) including the same pre-chemotherapy and post-chemotherapy GM-CSF sequences (Mann and Edmonson, unpublished) . No complete tumor regressions were observed (four PR) and all of the three patients surviving more than two years have progressive unresectable disease without hope for cure, despite our use of sargramostim doses which were twice those usually recommended for bone marrow stimulation and which were approximately the molar equivalent of our molgramostim doses. Nothing exceptional was recognized in the therapeutic outcome of this small group of sargramostim treated patients.
Although medical history is rife with small phase II reports yielding positive therapeutic results which were later contradicted by large randomized multi-institutional comparisons, the previously mentioned phase II EORTC study involved many institutions, and it revealed that 45% of 104 patients with advanced soft tissue sarcomas experienced objective tumor regression (10% CR) when molgramostim accompanied the chemotherapy [3] . Understandably the authors of the more recent EORTC study were surprised by their failure to reproduce this positive result in their phase III effort involving the substitution of sargramostim for molgramostim [2] . Unless some other clear and unequivocal explanation is found for this therapeutic failure these investigators might wish to do another comparative trial using molgramostim if a dependable source of this cytokine can be identified. As they stand currently these EORTC data may support our tentative hypothesis of an antisarcoma role for molgramostim.
Recombinant human GM-CSF has been expressed in mammalian cells, in yeast, and in E. coli cultures [7] . Neither the yeast derived nor the E. coli derived protein is identical to native GM-CSF. The yeast derived product, like the native human protein, has 127 amino acids and it is glycosylated, but the yeast derived product has leucine substituted for proline at the 23 position. The molecular mass of the yeast derived GM-CSF (sargramostim) is between 15.5 and 19.5 kd, depending upon the extent of molecular glycosylation. This is slightly lighter than the average 22 kd mass of the native human protein [8] , which also appears to be produced as a mixture of variably glycosylated molecules ranging from 14 to 35 kd [9] .
Molgramostim, the E. coli derived rhGM-CSF, has 121 amino acids and an extra methionine residue at position 1. Unlike GM-CSF produced in eukaryotic cells, molgramostim is a non-glycosylated protein of approximately 14.5 kd mass with pharmacokinetic properties and biologic activity somewhat different from the glycosylated products [7] . When assayed for stimulation of leukocytosis in monkeys, molgramostim was equivalent to regramostim (native human GM-CSF expressed in Chinese hamster ovary cells), if comparisons were made based purely on the protein moiety of the glycosylated natural product. As expected, the use of whole glycoprotein weight in computing doses for comparison with the non-glycosylated molgramostim required more of the glycosylated product to elicit the equivalent effect in rhesus monkeys as was seen with a given dose of molgramostim [10] . These authors observed no significant differences between the two products in stimulation of numbers of total leukocytes, neutrophils, eosinophils, monocytes, or lymphocytes when equivalent molar doses were used.
Differences between the leukocytosis stimulating activity of molgramostim and that of the glycosylated rhGM-CSF products based on molecular size can easily be corrected for molar equivalency in the clinic by simple dose adjustments, however some uncertainty remains concerning the effectiveness of such dose increments to correct for the higher target cell receptor affinity and the associated greater (as much as 6-20 fold) specific activity of the non-glycosylated products [11, 12] . Only following enzymatic deglycosylation were regramostim and sargramostim comparable to molgramostim in reactivity by radioimmunoassay or by specific biologic activity in stimulating thymidine incorporation into human purified mononuclear cells. Experimentally the unglycosylated molgramostim is more rapidly cleared from the plasma than the glycosylated products following intravenous injection [13] , thus frequent subcutaneous administration has become our customary clinical practice in the use of this agent. While the existence of a specific physiologic role for the carbohydrate moiety of the natural glycosylated protein is not clear, the modulation of tissue distribution (and protection from early degradation?) of this trace protein appears to be one biologically conservative result [14] . Perhaps, as suggested by Kaushansky, the addition of N-linked carbohydrate may also facilitate the secretion of GM-CSF and other glycoproteins by eukaryotic cells [15] . In a discussion of their molecular model of GM-CSF and its putative receptor binding site, Diederichs et al. observed that the glycosylation of asparagine 27 and asparagine 37 present in sargramostim and other glycosylated products seems to interfere with receptor binding [16] .
In truth we do not know whether the profound differences in target cell receptor affinities between molgramostim and sargramostim are significant in any biologically important way. We do know that the toxicity profiles of these products are somewhat different, with molgramostim consistently the more toxic when given in traditional bone marrow stimulating doses [7] . Conceivably, this more powerful receptor binding by molgramostim might increase both the extent and duration of effector cell stimulation, perhaps influencing functions such as secondary cytokine production and anticancer cytotoxicity [17] [18] [19] . One group of investigators have observed a suggestion of clinical antitumor activity by molgramostim even in the absence of chemotherapy, including partial tumor regression in a heavily pretreated liposarcoma patient [20] . Certainly we cannot currently exclude the possibility that in pharmacologic doses the more powerful receptor binding by molgramostim might form the basis for significantly greater augmentation of some host cytoimmune functions or other antitumor effects than can be provided by glycosylated GM-CSF products.
Perhaps we and possibly also the EORTC investigators may have serendipitously observed the enhancement of antisarcoma effects of cancer chemotherapy by a unique and non-natural GM-CSF protein that was being used simply for its bone marrow stimulating effects. This hypothesis could be pursued by careful experimental comparisons of the relative potencies of molgramostim and sargramostim for secondary cytokine production, cytoimmune function enhancement, and apoptosis enhancement in sarcomas. It could be further examined through randomized comparative clinical studies of active antisarcoma chemotherapy plus molgramostim versus the same chemotherapy plus sargramostim. Initially, however, a phase III clinical trial of this type in advanced sarcoma patients receiving chemotherapy should compare molgramostim versus filgrastim. Obviously, both agents will support neutrophil production, but molgramostim should provide a greater number of complete tumor regressions and long-term survivors if, in fact, it really can enhance the antisarcoma effects of chemotherapy. We are quite interested in identifying a source of molgramostim for this purpose.
